Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Allergan depression...

    Allergan depression drug fails trial, loses over Rs 100 crore expected sales

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-08T09:00:27+05:30  |  Updated On 17 Aug 2021 12:32 PM IST

    Stanicky said the data was the most anticipated release of the year and likely means that Allergan will lose what had been expected to be a $1 billion to $2 billion peak sales opportunity.


    U.S: Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 per cent after the bell.


    The failure comes as the company faces increasing pressure from activist shareholders such as billionaire hedge fund manager David Tepper, who has urged the drugmaker to consider selling itself.


    Allergan's shares have been lagging those of its industry peers on account of abandoned plans to sell some businesses, a disappointing 2019 revenue forecast and rising competition for several important drugs.


    "We expect a greater focus on strategic actions with activist push likely to continue to heighten with the May 1 shareholder meeting approaching shortly," RBC Capital Markets analyst Randall Stanicky said in a note.


    Stanicky said the data was the most anticipated release of the year and likely means that Allergan will lose what had been expected to be a $1 billion to $2 billion peak sales opportunity.


    Some analysts, however, were not surprised, pointing out that investors had low expectations from the trial.


    Allergan said the trials compared rapastinel and placebo, both in combination with antidepressant therapy (ADT) in patients with a major depressive disorder who showed a partial response to ADT. The company added that it expected to make a decision on these programs during the course of 2019.


    The failure comes just a day after the U.S. Food and Drug Administration approved a Johnson & Johnson nasal spray antidepressant, making it the first new type of treatment for the disorder in more than 30 years.


    Analysts had expected rapastinel, a fast-acting intravenous antidepressant, to likely rival the J&J drug, which is a chemical mirror image of anaesthetic ketamine.


    Allergan bought rapastinel in 2015 from its collaborator Aptinyx and added another depression drug from the company last year.


    The trial results highlighted the need for more options for people suffering from depression, with a large number of patients not responding to current treatments and some of the drugs carrying significant side effects.


    Depression is a common disorder that currently affects 300 million people of all ages globally, according to the World Health Organization, calling it the leading cause of disability.


    An interim analysis of the treatment in a relapse prevention study also indicated that the main goals will not be met, the company said.


    Allergan's shares were down 3.5 per cent at $132.70.


    Also Read: Health Canada places restrictions on Allergan Fibroid treatment Esmya

    ADTAllergananaesthetic ketamineantidepressant therapyDavid Tepperdepressiondepression drugJohnson & Johnsonnasal spray antidepressantRBC Capital MarketsStanickytreatmentU.S. Food and Drug AdministrationWHOWorld Health Organization
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok